Organon & Co (OGN)
Debt-to-equity ratio
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
---|---|---|---|---|
Long-term debt | US$ in thousands | 8,751,000 | 8,905,000 | 9,125,000 |
Total stockholders’ equity | US$ in thousands | -70,000 | -892,000 | -1,508,000 |
Debt-to-equity ratio | — | — | — |
December 31, 2023 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $8,751,000K ÷ $-70,000K
= —
The debt-to-equity ratio for Organon & Co. is not available for the years 2020, 2021, 2022, and 2023. However, based on the data provided, the debt-to-equity ratio for the year 2019 was 0.01, indicating that the company had a minimal level of debt relative to its equity in that year. Without the information for the subsequent years, it is difficult to assess any trend or analyze the company's leverage position over time. Further data for the missing years would be essential to evaluate the changes in the company's capital structure and financial risk.
Peer comparison
Dec 31, 2023
Company name
Symbol
Debt-to-equity ratio
Organon & Co
OGN
—
Abbott Laboratories
ABT
0.35
AbbVie Inc
ABBV
0.00
Alkermes Plc
ALKS
0.24
Amphastar P
AMPH
0.94
ANI Pharmaceuticals Inc
ANIP
0.66
Arcus Biosciences Inc
RCUS
0.00
Biomarin Pharmaceutical Inc
BMRN
0.12
Bristol-Myers Squibb Company
BMY
1.25
Catalent Inc
CTLT
0.00
Catalyst Pharmaceuticals Inc
CPRX
0.00